Browse by Administration Route

This page shows data for Subcutaneous virus.
Total Entries Retrieved: 41
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10086 YF-Vax Yellow fever Hemorrhagic Yellow fever virus positive-sense, single-stranded RNA Live-attenuated Approved Sanofi Pasteur NA France 9 months and above Single dose Subcutaneous NA 17D-204 strain of yellow fever virus Culturing 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos US FDA NA NA NA NA NA https://www.fda.gov/media/76015/download https://www.fda.gov/media/76015/download
10087 CYD-TDV Dengvaxia Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Approved Sanofi Pasteur 2015 France 9 - 45 years 3 doses 6 months apart Subcutaneous NA Dengue virus serotypes (1, 2, 3 and 4) 17D vaccine vector expressing genes of DENV-1, 2, 3, or 4 US FDA NA NA NA 30684747 NCT02747927 https://www.sciencedirect.com/science/article/pii/S1201971219300402 https://www.fda.gov/media/124379/download
10088 Weisairuiji Biovac-A Mevac-A Hepatitis A Hepatitic Hepatitis A virus positive-sense, single-stranded RNA Live-attenuated Approved Biogenetech Co. Ltd., Zhejiang Pukang Biotechnology Co. Ltd. 2010 Thailand 1.5 years and above Single dose Subcutaneous NA H2 strain of HAV H2-attenuated strain of HAV cultured in human diploid cells. China FDA, US FDA NA NA MEVAC-A 24280971 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/ https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf
10089 Weisairuiji Biovac-A Mevac-A Hepatitis A Hepatitic Hepatitis A virus positive-sense, single-stranded RNA Live-attenuated Approved Institute of Medical Biology, Chinese Academy of Medical Sciences NA China NA Single dose Subcutaneous NA H2 strain of HAV NA China FDA, US FDA NA NA NA 29661808 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/ https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1072530000811C-SPC.pdf
10090 HAVAC Hepatitis A Hepatitic Hepatitis A virus positive-sense, single-stranded RNA Live-attenuated Approved Changchun Institute of Biological Products NA China NA Single dose Subcutaneous NA LA-1 NA Government of Canada Changchun Changsheng Life Sciences NA NA 24280971 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/ https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
10091 HAVAC Hepatitis A Hepatitic Hepatitis A virus positive-sense, single-stranded RNA Live-attenuated Approved Changchun Institute of Biological Products NA China NA Single dose Subcutaneous NA LA-1 NA Government of Canada Changchun Changsheng Life Sciences NA NA 29661808 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/ https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
10123 SA14-14-2 (IXIARO) Viral encephalitis Neurologic West Nile virus positive-sense, single-stranded RNA Live-attenuated Approved Sanofi Pasteur 2013 Thailand NA NA Subcutaneous NA SA 14-14-2 Cell culture based NA NA NA NA 24161909 NCT01092507 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/ https://www.fda.gov/media/75777/download
10124 ENCEVAC Viral encephalitis Neurologic West Nile virus positive-sense, single-stranded RNA Inactivated Approved Research Foundation for Microbial Diseases of Osaka University NA NA NA NA Subcutaneous NA Beijing-1(P1) Cell culture based NA NA NA JEBIK V (BIKEN), KD-287, JEIMMUGEN INJ (Kaketsuken) 24161909 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/ https://ifli.wisc.edu/wp-content/uploads/sites/528/2019/05/Japanese-Encephalitis.pdf
10126 IMOJEV Viral encephalitis Neurologic West Nile virus positive-sense, single-stranded RNA Live-attenuated Approved Sanofi Pasteur 2017 Thailand 9 months and above 3 doses Subcutaneous NA SA 14-14-2 Mouse brain based US FDA NA NA ChimeriVax-JE, JE-CV, THAIJEV (Sanofi-Aventis) 24161909 NCT01900444 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/ https://www.fda.gov/vaccines-blood-biologics/vaccines/japanese-encephalitis-vaccine-inactivated-adsorbed
10132 JYNNEOS Smallpox Exanthous Variola virus double stranded DNA Live-attenuated Approved Bavarian Nordic NA Denmark 18 years and above 2 doses 4 weeks apart Subcutaneous NA Vaccinia Virus Ankar NA US FDA NA NA Imvamune, Imvanex, MVA-BN NA NA https://www.fda.gov/vaccines-blood-biologics/jynneos https://www.fda.gov/media/131078/download
10134 Priorix Measles, Mumps, Rubella, Chickenpox Exanthous Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus negative-sense, single-stranded RNA Live-attenuated Approved GlaxoSmithKline 2019 NA 11 months - 22 months 2 doses 42 days apart Subcutaneous NA Vaccinia Virus NA NA NA NA NA NA NCT00226499 https://www.fda.gov/vaccines-blood-biologics/priorix https://clinicaltrials.gov/ct2/show/NCT00226499
10135 Varivax Chickenpox Exanthous Varicella-zoster virus double stranded DNA Live-attenuated Approved Merck & Co. Inc. 2007 USA 1 - 12 years 2 doses (0.5 ml each) separated by at least 3 months.# First dose: age 12 through 15 months, Second dose: age 4 through 6 years Subcutaneous NA Oka/Merck strain of live-attenuated varicella virus NA US FDA NA NA NA NA NCT00822237 https://www.cdc.gov/vaccines/vpd/varicella/index.html https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
10136 Varivax Chickenpox Exanthous Varicella-zoster virus double stranded DNA Live-attenuated Approved Merck & Co. Inc. 2007 USA 12 - 23 months 2 doses 4 weeks apart Subcutaneous NA Oka/Merck strain of live-attenuated varicella virus NA US FDA NA NA NA NA NA https://www.cdc.gov/vaccines/vpd/varicella/index.html https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
10137 ProQuad Measles, Mumps, Rubella, Varicella Exanthous Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus negative-sense, single-stranded RNA Live-attenuated Approved Merck & Co. Inc. NA USA 1 - 12 years First dose at 12 through 15 months of age and Second dose at 4 through 6 years of age Subcutaneous NA NA NA US FDA NA NA NA NA NCT00985166 https://www.cdc.gov/vaccines/vpd/varicella/index.html https://www.fda.gov/vaccines-blood-biologics/vaccines/proquad
10149 OSE13E COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 OSE Immunotherapeutics 2021 Belgium 18 - 45 years 2 doses 21 days apart Subcutaneous NA 11 different proteins of SARS-CoV-2 virus NA NA NA NA CoVepiT NA NCT04885361 https://clinicaltrials.gov/show/NCT04885361 NA
10171 SARS-CoV-2 VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 The Scientific and Technological Research Council of Turkey 2021 Turkey 18 - 45 years 2 doses 21 days apart Subcutaneous Alumium hydroxide, CpG ODN Inactivated SARS-CoV-2 virus NA NA NA NA NA NA NCT04866069 https://clinicaltrials.gov/ct2/show/study/NCT04866069 NA
10172 COVID-19 aAPC vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Shenzhen Geno-Immune Medical Institute 2021 China 6 months - 80 years 3 doses on day 0, 14 and 28 Subcutaneous NA NA The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune-modulatory genes and the viral minigenes to the artificial antigen-presenting cells NA NA NA NA 33816047 NCT04299724 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10211 rDEN3delta30/31-7164 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Phase 1 National Institute of Allergy and Infectious Diseases 2013 USA 18 - 50 years NA Subcutaneous NA Dengue virus serotypes -3 NA NA Johns Hopkins Bloomberg School of Public Health NA NA NA NCT00831012 https://clinicaltrials.gov/ct2/show/NCT00831012?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=12 NA
10215 Delta 5nsP3 DREP-E MVA-CE Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 NA NA NA NA Single dose Subcutaneous NA CHIKV nsP3 envelope and capsid protein NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10233 IRES-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 1 University of Texas Medical Branch, Takeda Pharmaceutical Company Limited 2011 USA NA NA Subcutaneous NA La Reunion strain NA NA NA NA NA NA NA https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145802/
10251 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years NA Subcutaneous NA Spike & Nucleocapsid protein NA NA NA NA NA 33937326 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10262 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years Single dose Subcutaneous NA Spike & nucleocapsid protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10269 CoVac-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Hospital Tuebingen 2021 Germany 18 years and above Single dose Subcutaneous NA SARS-CoV-2 HLA-DR peptides NA NA NA NA IMP 33816047 NCT04954469 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10270 COVID-19 VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 The Scientific and Technological Research Council of Turkey 2021 Turkey 18 - 59 years 2 doses 21 days apart Subcutaneous Alum adsorbed, CpG ODN Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04962893 https://clinicaltrials.gov/ct2/show/NCT04962893 NA
10281 AKS-452 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Medical Center Groningen 2021 Netherlands 18 - 65 years NA Subcutaneous NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04681092 https://clinicaltrials.gov/show/NCT04681092 NA
10285 LV-SMENP COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Shenzhen Geno-Immune Medical Institute 2021 China 6 months and above NA Subcutaneous NA Covid-19 minigene SMENP and immune modulatory genes NA NA NA NA NA NA NCT04276896 https://clinicaltrials.gov/show/NCT04276896 NA
10298 CHIKV-NoLS Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Phase 2 NA NA NA NA Single dose Subcutaneous NA N-terminal region of capsid protein NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10300 EILV/CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 NA NA NA NA 8.8 log10 PFU (C57BL/6) or 8.5 log10 PFU (IFN?/?R–/–mice) of live EILV/CHIKV, single injection Subcutaneous NA EILV cDNA clone containing CHIKV structural proteins NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10302 CHIK-VLP Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 2 NA NA NA NA NA Subcutaneous NA CHIKV structural proteins introduced into yeast expression system NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10308 MVA-mBN85B Measles Exanthous Morbillivirus negative-sense, single-stranded RNA Recombinant viral vector Phase 2 Bavarian Nordic 2012 South Africa 6 months - 6 years 2 doses 4 weeks apart Subcutaneous NA Attenuated Modified Vaccinia Virus Ankara, strain encoding hemagglutinin protein, fusion protein and nucleoprotein of measles virus NA NA NA NA Rouvax NA NCT00891007 https://clinicaltrials.gov/ct2/show/NCT00891007?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=3 NA
10309 MeMuRu-OKA Measles, Mumps, Rubella, Varicella Exanthous Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus negative-sense, single-stranded RNA Live-attenuated Phase 2 GlaxoSmithKline 2016 Canada 15 months - 6 years NA Subcutaneous NA Jeryl Lynn strain, Schwarz strain, RA 27/3 strain, OKA strain NA NA NA NA NA NA NCT00352898 https://clinicaltrials.gov/ct2/show/NCT00352898 https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006065-14/DE
10363 STAMARiL Yellow fever Hemorrhagic Yellow fever virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Sanofi Pasteur NA France 10 months Single dose Subcutaneous NA 17D-204 strain of yellow fever virus Produced in specified pathogen-free chick embryos NA NA NA NA NA NA https://www.sanofipasteur.co.uk/-/media/ems/conditions/vaccines/brands/oneportal-ie/pdf/105_stamaril_mah_address_update_12_2017_uk.pdf NA
10364 TAK-003 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Takeda Pharmaceutical Company Limited NA USA 4 - 16 years NA Subcutaneous NA Dengue virus serotypes (1, 2, 3 and 4) Mammalian cell vero culture NA NA NA TDV 30684747 NA https://www.sciencedirect.com/science/article/pii/S1201971219300402 NA
10365 TV-003/005 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Merck & Co. Inc. NA Brazil 2 - 59 years NA Subcutaneous NA Dengue virus serotypes (1, 2, 3 and 4) Mammalian cell vero culture NA National Institute of Allergy and Infectious Diseases NA TetraVax-DV 30684747 NCT02406729 https://www.sciencedirect.com/science/article/pii/S1201971219300402 https://clinicaltrials.gov/ct2/show/NCT02406729
10370 JE-VAX Viral encephalitis Neurologic West Nile virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Research Foundation for Microbial Diseases of Osaka University NA China NA NA Subcutaneous NA Nakayama-NIH/Beijing-1(P1) strain Mouse brain based NA NA Asia SA 14-14-2 vaccine 24161909 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/ NA
10374 MRVAC Measles, Rubella Exanthous Morbillivirus, Rubella virus negative-sense, single-stranded RNA Live-attenuated Phase 3 Center for Research and Production of Vaccines and Biologicals 2018 Vietnam 1 - 45 years NA Subcutaneous NA Strain AIK-C measles virus clone with Takahashi rubella virus NA NA NA NA NA NA NCT03713359 https://clinicaltrials.gov/ct2/show/NCT03713359?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=54 NA
10375 OMB157 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 4 Novartis 2021 Germany 18 years and above NA Subcutaneous NA NA NA NA NA NA Ofatumumab NA NCT04869358 https://clinicaltrials.gov/show/NCT04869358 https://www.ema.europa.eu/en/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf
10379 Bulgarian vaccine Crimean-Congo haemorrhagic fever Hemorrhagic Nairovirus negative-sense, single-stranded RNA Inactivated Preclinical NA 1974 Union of Soviet Socialist Republics 16 years and above NA Subcutaneous Aluminum (aluminium hydroxide) NA Prepared from brain tissue of CCHFV infected newborn mice NA NA NA Zabdeno, Mvabea 32461819 NA https://www.liebertpub.com/doi/10.1089/biores.2019.0057 https://www.ema.europa.eu/en/documents/product-information/zabdeno-epar-product-information_en.pdf
10385 DeltaC-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Live-attenuated Preclinical NA NA NA NA Single dose Subcutaneous NA Capsid deletion NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA